Producción de un antisuero específico contra la cepa A/Johannesburg/33/94 (H3N2), y su utilidad en la caracterización de aislamientos de virus de influenza en ratas Wistar.

Production of a specific antiserum against strain A/Johannesburg/33/94 (H3N2), and its usefulness in
characterizing isolations of Influenza virus in Wistar rats.

Suset Oropesa, Francisco Calvi, Bárbara Hernández, Jorge Cantillo, Omayda Pérez, Irais Atencio, Angel Goyenechea

Instituto de Medicina Tropical Pedro Kourí (IPK). Novia del Mediodía. Km. 6 ½. La Lisa. Ciudad de La Habana. Cuba. Laboratorio Nacional de Influenza.

E-mail: s.oro@ipk.sld.cu, soro@infomed.sld.cu

RESUMEN

Se obtuvo un antisuero policlonal con alto título, alta especificidad y sensibilidad, contra la hemaglutinina de la cepa de influenza A/Johannesburg/33/94 que pertenece al subtipo A (H3N2). Se describe el proceso de obtención del antígeno o inmunógeno, el esquema de inmunización y su aplicación a las ratas Wistar como modelo animal; y se validó mediante la técnica de inhibición de la hemaglutinación (IH). El antisuero obtenido fue tratado con enzima destructora de receptores de producción nacional (EDR/IPK) para la eliminación de inhibidores inespecíficos de la IH. La validación se realizó frente a un panel que incluyó 9 cepas de referencia de influenza de los subtipos A(H3N2), A(H1N1) y el tipo B. No se detectaron reacciones inespecíficas frente a cepas A(H1N1) y del tipo B. Se determinó el tipo y subtipo de aislamientos autóctonos con resultados satisfactorios.

ABSTRACT

A polyclonal antiserum with high titer, great specificity and sensitivity was obtained against the hemagglutinin of Influenza A/Johannesburg/33/94, belonging to subtype A (H3N2). The obtaining process of the antigen or immunogen, the immunization schedule and its administration to Wistar rats as animal model are described. All of these were validated by the hemagglutinin inhibition technique. The antiserum obtained was treated with receptor-destroying enzymes of national production (EDR/IPK) in order to eliminate the unspecific inhibitors of the hemagglutinin inhibition. Validation was carried out in front of a panel including 9 influenza reference strains belonging to subtypes A(H3N2), A(H1N1), and to type B. No unspecific reactions against strains A(H1N1) and of type B were detected. Five autochthonous isolates were satisfactorily typed and subtyped.

Keywords: Influenza virus, polyclonal antisera, antigenic characterization, hemagglutination inhibition.

Texto completo formato PDF

REFERENCIAS

1. Fouchier R, Munster V, Wallensten A, Bestebroer T, Herfst S, Smith D. Characterization of a Novel Influenza A Virus Hemagglutinin Subtype (H16) Obtained from Black-Headed Gulls. Journal of Virology. 2005;79(5):2814-22.
2. Holmes EC, Ghedin E, Miller N. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol 2005;3(9): 300-310.
3. Kamps BS, Hoffman C, Preiser W, editores. Influenza Report. Flying Publisher; 2006 [citado el 3 de junio del 2006]. Disponible en: http://www.influenzareport.com.
4. Palmer D, Dowdle W, Coleman M, Shild G. Advanced laboratory techniques for influenza diagnosis. Immunology series N0 6. Part. 2: procedural guide US Department of Health Educat. And Public Health Service. 1975:25-62.
5. Swenson PD. Hemagglutination inhibition test for the identification of influenza viruses. En: Iceberg HD, editor. Clinical Micro-biology Procedures Handbook. Washington, DC: ASM, 1992:8-11.
6. International Epizootics Organizations. Manual of standards for diagnostic tests and vaccines: Influenza. 3a.ed. france: IEO, 1996.
7. Instituto de Medicina Tropical /OMS/ OPS/ISIIC. Manual de procedimientos para el diagnóstico de laboratorio de las infecciones respiratorias agudas de etiología viral. 1a. ed. Cuba. Noviembre, 2003.
8. Centers for Diseases Control and Prevention. Influenza Reagent kit for the identification of influenza isolates. Georgia: CDC, 1996.
9. WER.CDC. Influenza (Flu) . Influenza Summary, 2000-2001 Season. Report prepared: June, 2001. Disponible en: http://www.cdc.gov
10. WER. CDC. Influenza (Flu). Influenza Summary, 2004-2005 Season. Report prepared: July, 2006. Disponible en: http://www.cdc.gov
11. Centro Nacional para animales de laboratorio:Animales producidos y/o mantenidos en barreras. Cuba. CENPALAB,1995.
12. Kruse RH, pukkett WH, Richardson JH. Biological Safety Cabinetry. Clin Microb Rev 1991;4(2):207-241.
13. Couch RB, Kasel JA. Influenza. En: Lennette EH, Lennette DA, Lennette E, editores. Diagnostic procedures for viral, rickettsial and chlamydial infections.7a.ed.USA: American Public Health Associations, 1995.
14. Lowry OR, Rosebrowgh NJ, Randall RJ. Protein measurement with polinphenol reagent. J Biol Chem 1951; 193(20):265-275.
15. Takase H, murakami Y, endo A, Ikeuchi T. Antibody responses and protection in mice immunized orally against influenza virus. Vaccine 1996; 14(17/18):1651-1656.
16. Johansson B, Grajower B, Kilbourne E. infection permissive immunization with influenza virus neuroaminidase prevents weight loss in infected mice. Vaccine 1993; 11(10):1037-1039.
17. Murphy B, Robert G.Orthomixoviruses: Influenza. En: Fields BN, Knipe DM, Howley P. Fields Virology. Volumen 1. New York: Lippincott-Raven, 2001.
18. Almeida B, Gregoriadis G, Potter C, Jennings R. Immunopotentation of local and systemic humoral immune responses by ISCOMS, liposomes and FCA: role in protection against influenza A in mice. Vaccine 1993;11(13):1302-1309.
19. Potter C, Tamizar H, Jennings R. Immune response of mice to immunization with subunit influenza A. Vaccine 1995;13(3):253-260.
20. Yakhno MA, Yamnikova SS, Zakstelskaya L. Effective methods for production of antiserum to H3 hemagglutinin. Voprosy Virusologii 1978; 4(4):498-501.
21. Belshe RB, Couch RB, Glezen WP, Treanor JT. Live attenuated intranasal influenza vaccine. Vaccine 2002; 20:3429-30.
22. Tomoda T, Morita H, Kurashige T, Massab H. Prevention of influenza by intranasal administration of cold-recombinant, live attenuated influenza virus. Vaccine 1995;13(2):185-190.
23. Hilleman MR. Realities and enigmas of human viral influenza: patogénesis, epidemiology and control. Vaccine 2002; 20: 3068-87.
24. Sugaya N. Influenza. Nipón Rinsho 2003; 61 Suppl 2: 135-40.
25. Ellis J, Chakraverty P, Clewley J. Genetic and antigenic variation in the hemaglutinin of recently circulating human influenza A(H3N2) virus in the United Kingdom. Arch Virol 1995; 140(11): 1889-1904.
26. World Health Organization. Influenza: Antigenic activity of recent Influenza virus isolates and Influenza activity in the Southern hemisphere. Wkly Epidemiol Rec 1995; 70(39):277-280.
27. CDC. Update: Influenza activity - United States and Worldwide, 1995-96 season, and composition of the 1996-97 influenza vaccine. MMWR 1996;45:326-29.
28. National Advisory Committee on Immunization. Statement on influenza vaccination for the 1996-97 season. CCDR 1996;22:89-97.
29. WER.CDC. Influenza (Flu) . Influenza Summary, 2003-2004 Season. Report prepared: June, 2004. Disponible en: http://www 2a.cdc.gov